Sanofi, Teva Ink Deal to Develop Inflammatory Bowel Disease Treatment
October 7, 2023
Source: drugdu
123
Collaboration to focus on ulcerative colitis and Crohn’s disease.
Image Credit: Adobe Stock Images/SciePro
Sanofi and Teva Pharmaceuticals, a US subsidiary of Teva Pharmaceutical Industries Ltd., announced in a company press release plans to partner on development and commercialization of TEV’574, currently in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease. Under terms of the collaboration, Teva will receive an initial payment of $500 million with the potential to earn up to $1 billion in development and launch milestones.
“This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy,” said Richard Francis, president, CEO, Teva, in the aforementioned release. “This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honored to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimize development and global launches.”
Copyright©2024 Ddu. All rights reserved.
Read more on
- Over 5.7 billion! China’s dual antibody ADC goes global+1 November 21, 2024
- Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding? November 21, 2024
- Yangqi Medical Chip completes tens of millions of yuan in Pre-A round financing November 21, 2024
- Endovascular stent approved through priority green channel November 21, 2024
- Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified November 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
